Precigen

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Precigen (PGEN) reports strong Q1 performance and growth opportunities

Precigen's Q1 2023 earnings call highlighted financial strength, progress in innovative therapies, and a focus on cost-effective drug development.
The company's platforms like PRGM 2012 and UltraCAR show promise in treating challenging diseases, supported by a solid cash runway into late 2024.
While facing challenges in program transparency and target rights, Precigen's opportunities lie in rapid commercialization, personalized medicine, and market expansion.

Precigen (PGEN) reports strong Q2 performance and FDA alignment

Precigen (PGEN) shows promising performance with positive Phase I data for PRGN-2012 and cost-saving measures implemented.
Strengths lie in FDA confirmation, positive regulatory developments, and extended cash runway to 2025.
Challenges include safety follow-up, commercial readiness, and balancing program focus amidst cost-saving measures.
Opportunities arise from international licensure discussions, repeat dosing scenarios, and FDA alignment for accelerated approval.

Precigen (PGEN) projects strong growth in 2024 with key milestones

Precigen (PGEN) anticipates a significant year ahead with key milestones for PRGN-2012 and UltraCAR-T therapies.
Financially, the company aims to balance R&D investments with cost reductions to support strategic initiatives.
Analysts' inquiries and the focus on strengthening the balance sheet underscore the company's commitment to sustainable growth.

Precigen (PGEN) excels with PRGN-2012 gene therapy, poised for growth

Precigen (PGEN) showcased strong performance with PRGN-2012, supported by positive clinical trial outcomes and regulatory milestones.
While challenges like trial enrollment pace and market strategies exist, strategic initiatives and financial updates indicate a proactive approach to addressing them.
The company's focus on commercialization and workforce optimization presents opportunities for growth and market leadership in the gene therapy sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

–  Repeated administrations of PRGN-2012 were well-tolerated with no dose-limiting toxicities and no treatment-related adverse events greater than Grade 2 – –  Clinical data show strong response in RRP patients with 50% of patients in Complete Response, requiring no post-treatment surgeries, following PRGN-2012 treatment at Dose Level 2; All complete responders remain surgery-free post-treatment with a minimum follow up of 12 months – –  PRGN-2012 treatment at Dose Level 2 significantly reduced the need for surgeries in severe, aggressive RRP patients; Median number of RRP surgeries in 12-month period reduced from 6.5 pre-treatment to 0.5 post-treatment – –  Phase 2 study is enrolling patients with a total of 32 patients enrolled at Dose Level 2 to date – –  Company to outline regulatory strategy in RRP as US Food and Drug Administration ( FDA) discussions advance – –  Precigen to host R&D Day virtual event today at 4:30 PM ET – GERMANTOWN, Md. , Jan. 24, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announces positive Phase 1 dose escalation and expansion cohort data as of the January 12, 2023 cutoff for the investigational, potential first-in-class PRGN-2012 off-the-shelf (OTS) AdenoVerse™ immunotherapy in patients with recurrent respiratory papillomatosis (RRP).

Precigen Announces Positive Phase 1 Dose Escalation and Expansion Cohort Data for Investigational Off-the-Shelf PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis

–  Company achieved significant progress for its clinical pipeline in 2022  – –  Precigen to host R&D Day virtual event on January 24, 2023, at 4:30 PM ET to share safety and efficacy data from the Phase 1 dose escalation and expansion cohorts of PRGN-2012 AdenoVerse™ immunotherapy in recurrent respiratory papillomatosis (RRP) – GERMANTOWN, Md. , Jan. 11, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today presented pipeline and corporate updates at the 41st Annual J.P.

Precigen Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference

GERMANTOWN, Md. , Jan. 4, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company will host an investigator-led R&D event on January 24, 2023 at 4:30 PM ET to showcase the latest clinical advancements for the Company's investigational, first-in-class PRGN-2012 off-the-shelf (OTS) AdenoVerse™ Immunotherapy in recurrent respiratory papillomatosis (RRP).

Precigen to Host a Virtual R&D Event on January 24th to Share Safety and Efficacy Data from the Phase 1 Dose Escalation and Expansion Cohorts of PRGN-2012 AdenoVerse™ Immunotherapy in Recurrent Respiratory Papillomatosis

GERMANTOWN, Md. , Dec. 19, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will present a corporate and clinical overview at the 41st Annual J.P.

Precigen to Present at the 41st Annual J.P. Morgan Healthcare Conference

–   Single infusion of UltraCAR-T cells with or without lymphodepletion demonstrated robust expansion and persistence in blood and bone marrow – –   PRGN-3006 infusion with lymphodepletion resulted in a decrease in bone marrow blasts in 60% of heavily pre-treated patients – –   Single infusion of autologous PRGN-3006 cells resulted in 27% objective response rate (ORR) in heavily pre-treated relapsed or refractory (r/r) acute myeloid leukemia (AML)  patients infused following lymphodepletion – –  PRGN-3006 was well-tolerated with no dose-limiting toxicities (DLTs) reported to date – GERMANTOWN, Md. , Dec. 12, 2022 /PRNewswire/ -- Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today presented positive Phase 1 dose escalation data from the ongoing Phase 1/1b clinical study of PRGN-3006 UltraCAR-T® in patients with r/r AML and higher risk myelodysplastic syndromes (MDS) (clinical trial identifier: NCT03927261) at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract# 4633).

Precigen Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T® Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients

Precigen, Inc. (NASDAQ:PGEN ) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Steve Harasym - Vice President, Investor Relations Helen Sabzevari - President & Chief Executive Officer Harry Thomasian - Chief Financial Officer Conference Call Participants Jason Butler - JMP Securities Ben Burnett - Stifel Arthur He - H.C. Wainwright Jennifer Kim - Cantor Fitzgerald Operator Good day, and welcome to the Precigen Third Quarter 2022 Financial Results Conference Call.

Precigen, Inc. (PGEN) Q3 2022 Earnings Call Transcript

–   Company will host virtual R&D event in early January 2023, timed to coincide with the 41st Annual JP Morgan Healthcare Conference , to showcase complete clinical trial data from Phase 1 dose escalation and expansion cohorts of PRGN-2012 AdenoVerse ™  Immunotherapy in recurrent respiratory papillomatosis (RRP) – –   Company to present two abstracts at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition in December: PRGN-3006 UltraCAR-T® Phase 1 safety and efficacy data in acute myeloid leukemia (AML) and PRGN-3007 UltraCAR-T Phase 1/1b trial-in-progress in ROR1-positive hematological and solid tumors – –   Retired $144.0 million of outstanding convertible notes due in July 2023 resulting in $5.4 million in savings via the discount realized and interest savings – –   Cash, cash equivalents, short-term investments and restricted cash totaled $153.8 million as of September 30, 2022 – GERMANTOWN, Md. , Nov. 9, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced third quarter 2022 financial results and progress of clinical programs.

Precigen Reports Third Quarter 2022 Financial Results and Progress of Clinical Programs

GERMANTOWN, Md. , Nov. 2, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release third quarter 2022 financial results after the market closes on Wednesday, November 9, 2022.

Precigen to Announce Third Quarter 2022 Financial Results on November 9th

HeartBeam

Powerbridge Technologies Co Ltd

Penny stocks to buy for under $3 The post Penny Stocks To Buy Now: 3 To Watch Under $3 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy Now: 3 To Watch Under $3

GERMANTOWN, Md. , Sept. 21, 2022  /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today named Rutul R.

Precigen Names Rutul R. Shah Chief Operating Officer

GERMANTOWN, Md. , Sept. 1, 2022 /PRNewswire/ -- Precigen, Inc. (NASDAQ: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a fireside chat at the 2022 Wells Fargo Healthcare Conference in Boston, Massachusetts on Wednesday, September 7, 2022 at 11:35 AM ET.

Precigen to Participate in the 2022 Wells Fargo Healthcare Conference

Today, we circle back on Precigen, a biotech firm that was once part of Intrexon. Precigen is advancing several drug candidates in its pipeline and recently agreed to a divesture than significantly bolstered its financial situation.

Circling Back On Precigen

–  Proceeds include $170 million in upfront cash and up to $10 million earn-out over two years – GERMANTOWN, Md. , Aug. 22, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company has completed the sale of its wholly-owned non-healthcare subsidiary, Trans Ova Genetics, L.C.

Precigen Completes Sale of Non-Healthcare Subsidiary Trans Ova Genetics

Precigen, Inc. (NASDAQ:PGEN ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Steven Harasym - Vice President and Head of Investor Relations Helen Sabzevari - President and Chief Executive Officer Harry Thomasian - Chief Financial Officer Conference Call Participants Nick Abbott - Wells Fargo Securities, LLC Jason Butler - JMP Securities, LLC Jennifer Kim - Cantor Fitzgerald & Co. Operator Good day, and welcome to the Precigen Second Quarter and First Half 2022 Financial Results Conference Call. After today's presentation, there will be an opportunity to ask questions.

Precigen, Inc. (PGEN) CEO Helen Sabzevari on Q2 2022 Results - Earnings Call Transcript

Precigen, Inc. (PGEN) delivered earnings and revenue surprises of 18.75% and 83.41%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Precigen, Inc. (PGEN) Reports Q2 Loss, Lags Revenue Estimates

– Enrollment  complete in Phase 1 study of PRGN-3006 UltraCAR-T ® in acute myeloid leukemia (AML); enrollment ongoing in Phase 1b dose expansion study; Mayo Clinic in Rochester, Minnesota activated as first expansion site of Phase 1b multicenter expansion; technology transfer and site activation activities underway at multiple new sites – – Enrollment complete in Phase 1 study of PRGN-3005 UltraCAR-T in advanced ovarian cancer; enrollment complete at Dose Level 3 with lymphodepletion in the IV arm; Phase 1b expansion study initiated at Dose Level 3 with lymphodepletion prior to IV infusion; technology transfer and site activation underway for Phase 1b multicenter expansion – – Enrollment complete in Phase 1 study of PRGN-2012 AdenoVerse ™ Immunotherapy in recurrent respiratory papillomatosis (RRP); Phase 2 study initiated and rapidly progressing – – Enrollment complete in combination arm of Phase 1 study of PRGN-2009 AdenoVerse Immunotherapy in human papillomavirus (HPV)-associated cancers – – Entered into agreement to sell wholly-owned subsidiary Trans Ova Genetics for $170 million in upfront cash and up to $10 million earn-out over two years; close expected in Q3 2022; Company intends to pay senior convertible notes when due in July 2023 – – Cash, cash equivalents, short-term and long-term investments totaled $132.8 million as of June 30, 2022 – GERMANTOWN, Md. , Aug. 8, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced second quarter and first half 2022 financial results.

Precigen Reports Second Quarter and First Half 2022 Financial Results

GERMANTOWN, Md., Aug. 1, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release second quarter and first half 2022 financial results after the market closes on Monday, August 8, 2022.

Precigen to Announce Second Quarter and First Half 2022 Financial Results on August 8th

Precigen, Inc. (PGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Precigen, Inc. (PGEN) to Report a Decline in Earnings: What to Look Out for

Precigen, Inc. (PGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Precigen, Inc. (PGEN) Upgraded to Buy: Here's What You Should Know

Yesterday, Precigen Inc (NASDAQ: PGEN) agreed to sell its non-healthcare subsidiary to URUS. HC Wainwright says they are encouraged by the divestiture of the company's non-core business and believe management deserves much credit, especially against the backdrop of the.

This Analyst Believes Precigen's Non-Healthcare Divesture Removes Financial Overhang

Precigen Inc (NASDAQ: PGEN) has agreed to sell its subsidiary Trans Ova Genetics, an animal reproductive technologies company, to URUS, a holding company with cooperative and private ownership. The deal consideration includes $170 million in upfront cash and up to $10 million earn-.

Why Precigen Shares Are Gaining Today

–  Precigen enters into agreement to sell wholly-owned subsidiary Trans Ova Genetics to URUS for $170 million in upfront cash and up to $10 million earn-out over two years; close expected in Q3 2022 – –  Transaction, upon closing, will solidify balance sheet and the Company intends to pay the senior convertible notes when due in July 2023 – –  Divestiture of this non-healthcare subsidiary will largely complete Precigen's strategy to focus exclusively on healthcare – GERMANTOWN, Md. , July 5, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company has entered into a definitive agreement for the sale of its wholly-owned non-healthcare subsidiary, Trans Ova Genetics, L.C.

Precigen Enters into Agreement to Divest Non-Healthcare Subsidiary Trans Ova Genetics

GERMANTOWN, Md. , June 27, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a virtual panel discussion titled, "Targeted T Cell Therapies, Including Autologous CAR T, TCR and More" on Thursday, June 30, 2022, at 1:00 PM ET at the Stifel 2022 Virtual Cell Therapy Summit.

Precigen to Participate in the Stifel 2022 Virtual Cell Therapy Summit

GERMANTOWN, Md. , May 17, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a virtual fireside chat at the 2022 H.C.

Precigen to Participate in the 2022 H.C. Wainwright Global Investment Conference

Precigen, Inc. (PGEN) delivered earnings and revenue surprises of 28.57% and 53.21%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

News for Precigen Stock (PGEN)